Search

Issue
Title
Authors
Preclinical studies of cytotoxicity and cytostatic activity of five new imidazotriazine derivatives in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures
Al-Humairi A.H., Buldakov M.A., Novochadov V.V., Cherdyntseva N.V., Udut V.V.
Role of repeat biopsies of metastatic and recurrent lesions for the study of tumor heterogeneity in luminal breast cancer: Retrospective and prospective analyses
Gluzman M.I., Chistyakova E.A., Raskin G.A., Orlova R.V.
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D., Borisov D.A., Makarova M.V.
A clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report
Medvedev S.V., Vlasova M.Y., Bolotina L.V., Kaprin A.D., Khmelevskiy E.V., Zikiryakhodzhaev A.D., Khakimova S.G., Khakimova G.G., Bychkova N.M., Zaitseva N.A., Abushova E.R., Guseva S.D., Maslov E.D.
Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
New therapies for hormone-positive HER2-negative metastatic breast cancer with AKT signaling alterations: the Expert Panel Decision
Editorial B.
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)
Uvarova K.G.
Avastin in clinical chemotherapy of malignant tumors
Gorbunova V.A.
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
Sokolova T.N., Solov'eva T.I., Aleksakhina S.N., Janus G.A., Goryainova A., Gluzman M.I., Orlova R.V., Stukan A.I., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Sultanbaev A.V., Vorobeva E.N., Mikhaevich L.M., Pyliv V.N., Lysenko A.N., Khachmamuk Z.K., Kozlov A.E., Bakharev S.Y., Parsyan S.G., Rossokha E.I., Osidze L.D., Shumskaya I.S., Agaeva A.V., Kasmynina T.A., Klimenko V.V., Akhmetgareeva K.T., Vakhitova A.A., Chakhkieva M.D., Dmitriev V.N., Bakshun Y.I., Vasilyev A.E., Gasimly D.D., Kravchenko N.A., Maksimov D.A., Nesterova A.I., Sharvashidze I.O., Gadzaova C.H., Rakhmankulova G.G., Khamgokov Z.M., Amirkhanova I.K., Bembeeva L.V., Vladimirov V.I., Petrenko O. ., Ruskova N.G., Serikova E.L., Subbotina K.S., Tkachenko S.A., Chang V.L., Erdniev S.P., Barbara V.S., Vasilevskaya A.V., Mikheeva Y.V., Popova N.O., Startseva E.P., Fateeva A.V., Yukalchuk D.Y., Grechkina A.A., Musaeva K.S., Odintsova S.V., Stel'makh A.S., Khabibulaeva P.I., Khlobystina A.G., Shvaiko K.A., Basova E.A., Bogomolova I.A., Bolieva M.B., Goldberg V.E., Kibisheva M.V., Menshikov K.V., Ryazanov D.V., Stepanova M.L., Udalova Y.A., Shkradyuk A.V., Chapko Y.S., Shchukina A.A., Khabriev I.M., Kirtbaya D.V., Degtyarev A.M., Epkhiev A.A., Tyugina Y.A., Murachuev M.A., Togo A.V., Ievleva A.G., Imyanitov E.N.
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review
Sultanbaev A.V., Kolyadina I.V., Gilyazova I.R., Nasretdinov A.F., Musin S.I., Sultanbaeva N.I., Menshikov K.V.
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Frank G.A., Komov D.V., Karseladze A.I., Bastiaannet E., Dekker-Ensink N.G.
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Long-term aesthetic outcomes of reconstructive surgeries with endoprosthetics for breast cancer: A review
Khomidi U.K., Vlasova M.Y., Saribekyan E.K., Zikiryakhodzhaev A.D., Khakimova S.G., Khakimova G.G., Kodzoeva D.B.
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
Editorial B.
Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case
Radyukova I.M., Rats N.M.
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer
Kolyadina I.V., Danzanova T.Y., Khokhlova S.V., Trofimova O.P., Kovaleva E.V., Rodionov V.V., Poddubnaya I.V.
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
Kolyadina I.V., Poddubnaya I.V.
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan
Berdimyradova M.B., Khadjiev S.M., Khommadova D.N., Polatova G.O., Kakajanova A.O., Batyrov C.B., Penayev D.N., Agayeva B.G., Annaberdiyeva G.A.
Influence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study
Duadze I.S., Kaprin A.D., Zikiryakhodzhaev A.D., Reshetov I.V., Usov F.N., Rasskazova E.A., Sukhotko A.S., Starkova M.V., Bagdasarova D.V., Dzhabrailova D.S., Khakimova S.G.
Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer
Pavlikova O.A., Kolyadina I.V., Komov D.V., Vishnevskaya Y.V., Poddubnaya I.V.
Rare morphological forms of breast cancer: features of surgical approach
Vysotskaya I.V., Letyagin V.P., Kolyadina I.V., Martynova G.V.
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
Gordeeva O.O., Kolyadina I.V., Zhukova L.G., Gan'shina I.P., Komov D.V., Meshcheriakov A.A.
Prognostic value of p53 expression in patients with stage I breast cancer
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Liefers G.J., Dekker-Ensink N.G., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
Karabina E.V., Zhukova L.G.
Squamous cell breast cancer: description of a rare clinical case
Zikiryakhodjaev A.D., Khakimova S.G., Rasskazova E.A., Saribekian E.K., Omarova D.F., Surkova V.S., Khakimova G.G.
Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade
Lichinitser M.R., Semenov N.N.
Experience in the treatment of radioinduced angiosarcoma of the breast in a patient with primary multiple lesions of the breast and bladder. Case report
Semenov E.V., Gasymly D.D., Zyuzyukina A.V., Zukov R.A.
The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer
Vashenko L.N., Daschkova I.R., Bakulina S.M., Andreyko E.A.
PARP inhibitors in female reproductive system cancers
Pokataev I.A., Tyulyandin S.A.
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Chumakov P.M., Ilinskaya G.V., Bokhian V.Y., Sopova M.I.
Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study
Golubenko E.O., Savelyeva M.I., Poddubnaya I.V., Korennaya V.V.
Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study
Sultanbaev A.V., Menshikov K.V., Musin S.I., Nasretdinov A.F., Fatikhova A.A., Izmailov A.A., Lipatov O.N., Ayupov R.T., Sultanbaeva N.I., Menshikova I.A., Serebrennikov G.A.
Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy
Benefits and limitations of breastfeeding for mothers with malignant tumors
Ladodo O.B., Iurova M.V., Khokhlova S.V., Rodionov V.V., Sheshko E.L., Zubkov V.V., Makieva M.I., Chutkova D.A., Akhapkina E.S., Degtyarev D.N.
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V.I., Bloshchinenko A.A., Abolmasov A.E., Vilensky A.A., Laskov M.S.
Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
Zabotina T.N., Chertkova A.I., Borunova A.A., Kushlinskii N.E., Gershtein E.S., Zakharova E.N., Shoua E.K., Tsiklauri V.T., Samoylenko I.V., Khoroshilov M.V., Kadagidze Z.G.
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K.S., Filonenko D.A., Sukhova M.V., Zhukova L.G.
Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study
Golubenko E.O., Savelyeva M.I., Korennaya V.V., Podzolkova N.M., Valiev T.T.
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Tupitsyn N.N.
Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence
Editorial B.
Can any breast skin thickening be staged as T4?
Amosova V.A., Petrovskii A.V., Karpova M.S., Ponedel’nikova N.V., Frolova M.A.
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Mazurina N.V., Artamonova E.V., Beloyartseva M.F., Volkova E.I., Ganshina I.P., Troshina E.A., Tjulandin S.A., Chubenko V.A.
Opportunities for metastatic triple negative breast cancer therapy
Ganshina I.P., Gordeeva O.O., Manukyan M.S.
Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?
Trigolosov A.V., Uimanov V.A., Chernikh M.V., Petrovskiy A.V., Nikitina E.A., Nechushkin M.I.
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
Semiglazova T.Y., Dashyan G.A., Semiglazov V.V., Zhabina A.S., Osipov M.A., Kotova Z.S., Klimenko V.V., Krivorotko P.V., Semiglazov V.F.
Male breast cancer: review of the literature
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I.
Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A.
Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya
Myasnikova M.O.
Prognostic significance of androgen receptor expression in triple-negative breast cancer
Panchenko I.S., Panchenko S.V., Sharafutdinov M.G., Rodionov V.V., Kometova V.V., Burmenskaya O.V.
Isolated metastasis to the scalp in occult breast cancer: a clinical case
Ognerubov N.A., Sergeev R.S., Hizhnyak A.O., Ognerubova M.A., Dzhabrailov M.A.
Relationship of the integrin profile of the primary tumor to metastasis to regional lymph nodes in breast cancer
Zavyalova M.V., Kuznecov G.A., Grigoryeva E.S., Tashireva L.A., Pismenny D.S., Perelmuter V.M.
Breast cancer: genetic personal risk factors: A review
Zolotykh M.A., Bilyalov A.I., Nesterova A.I., Gimranov A.M., Filina J.V., Rizvanov A.A., Miftakhova R.R.
Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Burov D.A., Tupitsyn N.N.
Antiangiogenic therapy for breast cancer with triple negative phenotype
Ganshina I.P., Ivanova K.A., Gordeeva O.O., Arkhipov A.V., Zhukova L.G.
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
Poddubnaya I.V., Gligorov J., Zhukova L.G., Kovalenko E.I., Frolova M.A.
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V.
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S.
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
Kolyadina I.V., Poddubnaya I.V.
Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board
Artamonova E.V., Gorbunova V.A., Zhukov N.V., Manzjuk L.V., Manihas A.G., Paltuev P.M., Semiglazov V.F., Semiglazova T.Y., Stenina M.B., Tjuljandin S.A., Chubenko V.A.
Effektivnost' ad\"yuvantnoy terapii anastrozolom i tamoksifenom u patsientok s rannimi stadiyami raka molochnoy zhelezy (analiz dannykh issledovaniya ATAC pri mediane vremeni nablyudeniya 100 mes)
Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A.
Sovremennye vozmozhnosti lekarstvennoy terapii operabel'nogo raka molochnoy zhelezy (po materialam St. Gallen, 2005)
Letyagin V.P., Vysotskaya I.V.
«Problema optimizatsii ad\"yuvantnoy endokrinnoy terapii na rannikh stadiyakh raka molochnoy zhelezy»
Semiglazov V.F., Poddubnaya I.V.
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study
Sultanbaev A.V., Kolyadina I.V., Menshikov K.V., Musin S.I., Nasretdinov A.F., Sultanbaeva N.I., Rakhimov R.R., Lipatov D.O., Menshikova I.A., Izmailov A.A., Lipatova E.E.
Use of psychological interventions in women diagnosed and under treatment for non-metastatic breast cancer [Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review]
Mustafina F.U.
Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes
Snegovoy A.V., Kononenko I.B.
Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study
Savelyeva M.I., Golubenko E.O., Sozaeva Z.A., Poddubnaya I.V., Korennaya V.V.
Triple-negative breast cancer: new options for systemic targeted therapy. A review
Andreev D.A., Zavyalov A.A.
Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021
Editorial B.
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
Samaneva N.I., Vladimirova L.I., Kolyadina I.V., Frantsiyants E.M., Storozhakova A.E., Bandovkina V.A., Kalabanova E.A., Kabanov S.N., Svetitskaya I.V., Tishina A.V., Ezhova M.O.
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Frolova M.A., Kochetkova Y.I., Chubenko V.A., Volkov N.M., Moiseenko F.V., Garmarnik T.V., Ponomarenko D.M., Orlov A.E., Kostalanova Y.V., Makarycheva Y.Y., Nizegorodzeva A.A.
Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer
Nenakhova Y.N., Lyadov V.K., Poddubnaya I.V.
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
Artamonova E.V.
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
Artamonova E.V.
The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
Frolova M.A.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
Ahmetzanov F.S., Ahmetzanova F.F.
New chemotherapy options for triple-negative breast cancer (review of literature)
Sekundova M.A., Zdvizhkov A.M., Borisov V.I.
Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin
Borisova E.I., Voronina I.Y., Gutorov S.L.
Odnomomentnye mastektomii i laparoskopicheskie ovariektomii v lechenii raka molochnoy zhelezy
Khvastunov R.A., Kireev A.V., Nikol'skiy I.V., Suvorov V.A.
Opyt primeneniya Regional'noy programmy v g. Krasnodare
Mitashok I.S.
Immunological predictors of the therapeutic efficacy of atezolizumab in combination with nab-paclitaxel in metastatic triple-negative breast cancer: A pilot multicenter retrospective associative study
Kalinchuk A.Y., Popova N.O., Gofman A.A., Usoltseva I.S., Perelmuter V.M., Tashireva L.A.
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L.G., Bolotina L.V., Dvornichenko V.V., Fadeeva N.V., Ganshina I.P., Grechukhina K.S., Hasanova A.I., Kislov N.V., Kudryavtsev I.Y., Manikhas A.G., Musaeva N.E., Nizhegorodtseva A.A., Sadikova O.E., Sakaeva D.D., Snegovoy A.V., Stroyakovskiy D.L., Tjulandin S.A., Trishkina E.A., Vladimirova L.I., Volkov N.M., Kostalanova Y.V.
The effect of hormonal contraception on the risk of breast cancer: A review
Iurova M.V., Mezhevitinova E.A., Yakushevskaya O.V., Rodionov V.V., Prilepskaya V.N.
Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: a regional analysis
Valiachmetova C.K., Siraev E.R., Izmailov A.A.
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
Sokolova T.N., Aleksakhina S.N., Yanus G.A., Sultanbaev A.V., Menshikov K.V., Lysenko A.N., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Rossokha E.I., Bakharev S.Y., Basova E.A., Kasmynina T.A., Shumskaya I.S., Bakshun Y.I., Musaeva K.S., Khasanova A.I., Dmitriev V.N., Bolieva M.B., Gadzaova C.H., Petrenko O.L., Maksimov D.A., Vladimirov V.I., Goldberg V.E., Popova N.O., Kibisheva M.V., Khamgokov Z.M., Vasilyev A.E., Iyevleva A.G., Imyanitov E.N.
The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
Tabakov D.V., Zabotina T.N., Chanturia N.V., Zakharova E.N., Vorotnikov I.K., Selchuk V.Y., Sokolovskiy V.V., Petrovsky A.V.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case
Kolyadina I.V., Ganshina I.P., Zhukova L.G., Abdullaev A.G., Andreeva Y.Y., Danzanova T.Y., Sinyukova G.T., Komov D.V., Kozlov N.A., Filonenko D.A., Gordeeva O.O., Lubennikova E.V.
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Radiation-induced lung injury in breast cancer patients after breast conservation therapy
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom
Zhukova L.G., Abramov M.E., Vakhabova Y.V., Lud A.N., Obukhov A.A., Lichinitser M.R.
Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii
Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy?
Ptushkin V.V.
1 - 100 of 174 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"